What exactly did Morgan Stanley do on February 17, 2026 for LH?

Morgan Stanley maintained an **Overweight** rating on Labcorp Holdings Inc. (LH) on February 17, 2026 and said updated guidance should be well received. No new price target was published in the note.

How did the market react to the LH analyst rating update?

The stock moved modestly after the note, down **-0.63%** or **-$1.75** near the timestamp. The muted response reflects a maintained rating rather than a surprise upgrade or downgrade.

What should investors do after this LH analyst rating was maintained?

Investors should treat the maintained Overweight as a positive signal but watch upcoming guidance, earnings, and any new price targets. Reassess allocation against peers and risk factors like testing demand and reimbursement.

How does Meyka AI view LH after the maintained rating?

Meyka AI rates LH with a grade of **B+** based on benchmark, sector, growth, metrics, and analyst consensus. Use the grade as one input among research and not as investment advice.

Analyst Ratings

Morgan Stanley Maintains Overweight on Labcorp Holdings Inc. (LH) Feb 17, 2026

ByDanny Kontos February 18, 2026February 18, 2026

Morgan Stanley maintained its Overweight rating on Labcorp Holdings Inc. (LH) on February 17, 2026. This LH analyst rating action was flagged by TheFly and follows Labcorp guidance that Morgan Stanley says “should be well received”. The stock showed a short-term move of -0.63% or -$1.75 after the note. Market cap stands at $22,936,772,000 and no new price target was published in the bulletin.